Clinical Trials Browser

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplastic Cells, Circulating

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Recurrence

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence, Epstein-Barr Virus Infections, Multiple Acyl Coenzyme A Dehydrogenase Deficiency

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Clinical Trials

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

PLATINUM

DIAMOND

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

GEMSTONE

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

NPC-Nivo

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

GNT Induction Treatment in Locally Advanced NPC

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage

Hepatic Artery Infusion Pump for NPC Liver Metastases

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

NPC

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma